Comparison of two chemotherapeutic drug combinations for lung cancer.
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Advanced non-small cell lung cancer( adenocarcinoma) patientsHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungHealth Condition 3: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungHealth Condition 4: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2019/05/019130
- Lead Sponsor
- Government medical college hospital Trivandrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 151
Inclusion Criteria
1.Histologically confirmed cases of non small cell lung cancer â??adenocarcinoma
2.Stage 3B and Stage 4.
3.EGFR nonmutated or not done.
4.Eastern cooperative oncology group (ECOG) performance status of 1 or 2.
5.Previously untreated cases.
6.Normal bone marrow function(Hb >10, TC >4000, PLC >1Lakh)
7.Normal renal function (serum creatinine < 1.6)
8.Normal liver function.
Exclusion Criteria
1.Patients not willing to give a written consent.
2.History of previous malignancies treated or untreated.
3.Clinically significant cardiovascular disease, haemorrhagic diasthesis ,peripheral neuropathy ,coagulopathy.
4.EGFR mutated.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor response to Pemetrexed / Carboplatin versus Paclitaxel / Carboplatin in advanced Non Small Cell Lung Cancer(adenocarcinoma)Timepoint: 12 weeks from start of chemotherapy
- Secondary Outcome Measures
Name Time Method The progression free survival. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: Till one and half year from start of study;The toxicity profile <br/ ><br>Timepoint: After each chemotherapy cycle